CORK, IRELAND--(Marketwire - Jan 31, 2013) - QUMAS today announced significant growth through 2012, providing further evidence of its leadership position in Quality, Regulatory and Compliance Management across Life Sciences. The company delivered 25% growth in revenues in 2012 and grew its client base significantly.
QUMAS continued to add new names to its client list in 2012, including Polypeptide, Aveo, Revance, Samsung Bioepis, Pharmacyclics, Coating Place, PharmaNet/i3, ZioPharm, Emergent Biosolutions, Shionogi, and Alvogen. A number of these new clients have deployed and gone live with QUMAS ComplianceSP on Microsoft SharePoint 2010. Among other deals, QUMAS was engaged by a top 10 global biopharmaceutical company in 2012 to replace a legacy eDMS with the QUMAS Compliance Platform.
"This significant strengthening of our client base over the last 12 months reflects our continuing drive to be the dominant player in the space. This is further evidenced by the successful delivery of ComplianceSP, our SharePoint 2010-based solution," said Kevin O'Leary, CEO, QUMAS. "New client opportunities were up threefold in 2012 on 2011, and we're continuing to see significant growth in our pipeline."
The QUMAS Compliance Platform delivers comprehensive document, content and process management to the Regulatory, Quality and Compliance groups across Life Sciences, driving regulatory compliance and ultimately delivering business performance improvements.
QUMAS will be announcing a series of new client acquisitions over coming weeks.
QUMAS is the leader in Compliance Solutions with more than 270 global customer deployments and two decades of experience in highly regulated industries.
QUMAS is a Gold Microsoft Partner, and provides the QUMAS Compliance Platform on SharePoint 2010, Oracle or SQL. For more information, visit www.qumas.com